Stroke:女性缺血性卒中联用尿酸治疗效果更佳

2015-07-13 MedSci MedSci原创

 由于高耗氧导致的氧化损伤对于缺血性脑损伤有很大的危害。尿酸是嘌呤代谢的最终产物,是一种潜在的抗氧化物。尿酸的作用包括了清楚羟基自由基、过氧化氢和过氧硝酸盐等。目前,治疗急性缺血性卒中使用抗氧化药物和血栓溶解药物组合的处方,但是男女对这一处方是否有着相同的响应尚未明确。因此,研究人员分析了使用阿替普酶治疗急性缺血性卒中的患者对于尿酸疗法的响应的性别差异。在一项联用尿酸的临床试验中,206

由于高耗氧导致的氧化损伤对于缺血性脑损伤有很大的危害。尿酸是嘌呤代谢的最终产物,是一种潜在的抗氧化物。尿酸的作用包括了清楚羟基自由基、过氧化氢和过氧硝酸盐等。目前,治疗急性缺血性卒中使用抗氧化药物和血栓溶解药物组合的处方,但是男女对这一处方是否有着相同的响应尚未明确。因此,研究人员分析了使用阿替普酶治疗急性缺血性卒中的患者对于尿酸疗法的响应的性别差异。在一项联用尿酸的临床试验中,206名女性受试者和205名男性受试者被随机分组,使用1000mg尿酸或者安慰剂。在对这项临床试验进行再次分析,主要的结果是90天时优秀的结果比例。

使用尿酸进行治疗的111名女性中47人(42%)是优秀的结果,安慰剂组95人中28人为优秀的结果。男性中,两组的优秀结果的比例分别为36%和34%。治疗和性别显著地与优秀结果有着相互作用。因此,女性使用尿酸疗法可以获得相对于安慰剂的两倍的疗效。但是,这一疗法对于男性来讲,并没有这种效果。此外,治疗和血清尿酸水平之间的相互作用对于栓塞生长也只在女性受试者中较为显著。

此次研究发现患有急性缺血性卒中的女性使用阿替普酶进行治疗,并且联用尿酸可以减少栓塞的生长,并且相对于安慰剂组,可以获得更好的治疗效果。这对于临床治疗急性缺血性栓塞有着重要的指导意义。

原始出处:

Laura Llull et al. Uric Acid Therapy Improves Clinical Outcome in Women With Acute Ischemic Stroke. Stroke. 2015;46 DOI: 10.1161/STROKEAHA.115.009960

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806016, encodeId=69a518060161c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Oct 13 17:58:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893898, encodeId=01fb18938989d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Nov 24 12:58:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892661, encodeId=817718926619a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Sep 27 11:58:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32678, encodeId=8e23326e834, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32679, encodeId=c354326e9a1, content=有启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806016, encodeId=69a518060161c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Oct 13 17:58:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893898, encodeId=01fb18938989d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Nov 24 12:58:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892661, encodeId=817718926619a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Sep 27 11:58:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32678, encodeId=8e23326e834, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32679, encodeId=c354326e9a1, content=有启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806016, encodeId=69a518060161c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Oct 13 17:58:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893898, encodeId=01fb18938989d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Nov 24 12:58:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892661, encodeId=817718926619a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Sep 27 11:58:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32678, encodeId=8e23326e834, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32679, encodeId=c354326e9a1, content=有启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806016, encodeId=69a518060161c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Oct 13 17:58:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893898, encodeId=01fb18938989d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Nov 24 12:58:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892661, encodeId=817718926619a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Sep 27 11:58:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32678, encodeId=8e23326e834, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32679, encodeId=c354326e9a1, content=有启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2015-07-13 保守主义

    有意思

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1806016, encodeId=69a518060161c, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Oct 13 17:58:00 CST 2015, time=2015-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893898, encodeId=01fb18938989d, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Nov 24 12:58:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892661, encodeId=817718926619a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Sep 27 11:58:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32678, encodeId=8e23326e834, content=有意思, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=32679, encodeId=c354326e9a1, content=有启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Mon Jul 13 23:14:00 CST 2015, time=2015-07-13, status=1, ipAttribution=)]
    2015-07-13 保守主义

    有启发

    0

相关资讯

新型口服抗凝药预防亚洲人群非瓣膜房颤患者卒中的优势

首先张玉生教授介绍了亚洲AF患者的特点和传统抗栓治疗。根据流行病学调查研究显示亚洲AF疾病负荷将持续增加,尤其是中国,到2050年中国男性房颤患者将达到250万,女性房颤患者将达到310万。多个大型RCT研究(如RE-LY、ROCKET、ARISTOTLE、ENGAGE)或注册研究(如REALISE、RELY、RECORD)结果均显示亚洲AF患者

JAMA:卒中加快了认知能力的下降,并且影响时间长

    认知能力下降是卒中患者残疾的主要病因。卒中后幸存者的认知变化的幅度是不确定的。该研究的目的是为了探讨卒中事件幸存者中认知功能的变化,为他们卒中前认知的轨迹进行控制。    该前瞻性研究共有23572名≥45岁的参与者,这些参与者来自于卒中的地理和种族差异的原因(REGARDS)队列,并且无基线的认知障碍,居住在美国大陆,2003-2007招募进来并随

Neurology:环孢霉素不能有效缩小脑梗死范围

我们的研究目的为检测静脉注射环孢霉素结合溶栓治疗能否缩小脑梗死范围。研究方法:患者的年龄在18至85岁,呈现前循环卒中并适合溶栓治疗,登记加入此次多中心、单盲的对照实验。随机化后15分钟,患者接受静脉快速注射2.0 mg/kg环孢霉素(Sandimmune, Novartis)或者安慰剂。初级终末点为30天时通过MRI获得的梗死体积。次级终末点包括动脉闭塞不同位置(近端/远端)的梗死体积以及溶栓后

小卒中,怎样处理才不会成为“大麻烦”?

小卒中一直以来受到专家学者的重视,但过去学术上通常将其称为“静止性卒中”。2008年世界卒中日的主题是“: 小卒中,大麻烦”,时任《卒中》(Stroke)主编的哈金斯基(Hachinski)指出,如果对小卒中患者进行认真检查,仍可发现其存在轻微神经系统异常体征或轻度神经心理受损,因此将小卒中等同于“静止性卒中”并不恰当,对其更恰当的命名应为“亚临床卒中”,而小卒中的范围应包括亚临床卒中和与